# US 2026/0218171 A1 · Expanding applications of zgtc alphabet in protein expression and gene editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218171 A1
- Document ID: US20260218171A1
- Status: Published application
- Kind: A1
- Application number: 19/141,883
- Filed: 2023-12-22
- Published: 2026-07-30
- Earliest claimed: 2022-12-22
- Assignees: Trustees of Tufts College
- Applicants: Trustees of Tufts College
- Inventors: Shuliang Gao; Qiaobing Xu
- Web page: https://patentgrep.com/patent/US20260218171A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/333: Modified A
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are nucleic acids comprising a 2-aminoadenine (Z) base, and their uses in protein expression and gene editing. Standard ATGC-DNA (A-DNA) and AUGC-RNA (A-RNA) are composed of four standard nucleotides, each with a different nucleobase: adenine (A), thymine (T)/Uridine (U), guanine (G), and cytosine (C). These nucleobases form the genetic alphabet, ATGC, which make up the base pairs that follow Watson-Crick base-pairing rules, which are conserved across almost all domains of life. Why nature has evolved to primarily use these two base pair combinations remains one of the greatest mysteries in science.

## Claims

### Claim 1

A nucleic acid, comprising less than or equal to 2,500 nucleotides, wherein at least 15% of said nucleotides comprise a 2-aminoadenine (Z) base.

### Claim 2

The nucleic acid, comprising less than or equal to 2,000 nucleotides.

### Claim 3 (depends on 1, 2)

The nucleic acid of claim 1 or 2, wherein at least 38% or at least 39% of said nucleotides comprise a Z base.

### Claim 4 (depends on 1, 2, 3)

The nucleic acid of any one of claims 1-3, wherein the nucleic acid does not comprise an adenine (A) base.

### Claim 5 (depends on 1, 2, 3, 4)

The nucleic acid of any one of claims 1-4, wherein the nucleic acid comprises at least 100 or at least 160 nucleotides.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The nucleic acid of any one of claims 1-5, wherein the nucleic acid is a DNA comprising at least one intron, a cDNA, or an mRNA.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid of any one of claims 1-6, wherein the nucleic acid is an mRNA comprising a poly(Z) tail.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleic acid of any one of claims 1-7, further comprising at least one chemical modification.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A vector, comprising a nucleic acid of any one of claims 1-8.

### Claim 10 (depends on 9)

The vector of claim 9, wherein the vector is an expression vector.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of expressing or producing a protein, comprising contacting a cell with a nucleic acid of any one of claims 1-8, or with a vector of claim 9 or 10.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cell is a prokaryotic cell or a eukaryotic cell.

### Claim 13

A composition or kit, comprising:
(a) a Cas12a RNA-guided endonuclease or a nucleic acid encoding the Cas12a RNA-guided endonuclease; and
(b) a Cas12a crRNA comprising at least one Z base.

### Claim 14 (depends on 13)

The composition or kit of claim 13, wherein the Cas12a crRNA comprises at least 7 Z bases.

### Claim 15 (depends on 13, 14)

The composition or kit of claim 13 or 14, wherein the Cas12a crRNA does not comprise an A base.

### Claim 16 (depends on 13, 14, 15)

The composition or kit of any one of claims 13-15, wherein the Cas12a RNA-guided endonuclease is LbCas12a (LbCpf1).

### Claim 17

A method of cleaving or modifying a target DNA, comprising:
contacting the target DNA or a cell comprising the target DNA with:
(a) a Cas12a RNA-guided endonuclease, or a nucleic acid encoding the Cas12a RNA-guided endonuclease; and
(b) a Cas12a crRNA comprising at least one Z base,
wherein the Cas12a RNA-guided endonuclease and the Cas12a crRNA form a complex that cleaves or modifies the target DNA.

### Claim 18 (depends on 17)

The method of claim 17, wherein the Cas12a crRNA comprises at least 7 Z bases.

### Claim 19 (depends on 17, 18)

The method of claim 17 or 18, wherein the Cas12a crRNA does not comprise an A base.

### Claim 20 (depends on 17, 18, 19)

The method of any one of claims 17-19, wherein the Cas12a RNA-guided endonuclease is LbCas12a.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, wherein the target DNA is a plasmid DNA.

### Claim 22 (depends on 17, 18, 19, 20, 21)

The method of any one of claims 17-21, wherein the Cas12a crRNA comprising at least one Z base induces higher cleavage of the target DNA compared to the corresponding Cas12a crRNA wherein each of the at least one Z base is substituted with an A base.

### Claim 23 (depends on 22)

The method of claim 22, wherein the Cas12a crRNA comprising at least one Z base induces at least 1.1-fold cleavage of the target DNA compared to the corresponding Cas12a crRNA wherein each of the at least one Z base is substituted with an A base.

### Claim 24 (depends on 23)

The method of claim 23, wherein the Cas12a crRNA comprising at least one Z base induces 1.2-fold, 1.4-fold, 1.8-fold, 3.3-fold, or 6-fold cleavage of the target DNA compared to the corresponding Cas12a crRNA wherein each of the at least one Z base is substituted with an A base.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 17-24, wherein the Cas12a crRNA comprises at least one Z base in the seed region.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 17-25, wherein the Cas12a crRNA comprises a 20-nt guide sequence complimentary to a target DNA site with an A or Z content from 15% to 35%.

### Claim 27 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 17-26, wherein the Cas12a crRNA comprises a 20-nt guide sequence complimentary to a target DNA site with an AT or ZT content from 45% to 75%, or from 45% to 85%.

### Claim 28 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 17-27, wherein the target DNA comprises a 5′-TTTA, 5′-TTTC, or 5′-TTTG PAM motif.

### Claim 29 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 17-28, wherein the target DNA comprises a T-base at position 5′-PAM-6, 8, 10, 18, 19-3′.

### Claim 30 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 17-29, wherein the target DNA comprises at least one Z base.

### Claim 31

A method of improving cleavage activity or editing efficiency of a complex comprising a Cas12a RNA-guided endonuclease and a Cas12a crRNA, comprising substituting at least one A base of the Cas12a crRNA with a Z base.

### Claim 32 (depends on 31)

The method of claim 31, comprising substituting all A bases of the Cas12a crRNA with Z bases.

### Claim 33 (depends on 31, 32)

The method of claim 31 or 32, comprising substituting at least one A base of the DNA substrate with a Z base.

### Claim 34 (depends on 31, 32, 33)

The method of any one of claims 31-33, comprising substituting all A bases of the DNA substrate with Z bases.

### Claim 35

A method of cleaving or modifying a target DNA comprising at least one Z base, comprising:
contacting the target DNA or a cell comprising the target DNA with:
(a) a Cas12a RNA-guided endonuclease or a nucleic acid encoding the Cas12a RNA-guided endonuclease; and
(b) a Cas12a crRNA or a nucleic acid encoding a Cas12a crRNA,
wherein the Cas12a RNA-guided endonuclease and the Cas12a crRNA form a complex that cleaves or modifies the target DNA comprising at least one Z base.

### Claim 36

A composition or kit, comprising:
(a) a Cas9 protein or a nucleic acid encoding the Cas9 protein;
(b) a Cas9 crRNA comprising at least one Z base; and
(c) a Cas9 tracrRNA.

### Claim 37 (depends on 36)

The composition or kit of claim 36, wherein the Cas9 crRNA comprises at least 12 Z bases.

### Claim 38 (depends on 36, 37)

The composition or kit of claim 36 or 37, wherein the Cas9 crRNA does not comprise an A base.

### Claim 39 (depends on 36, 37, 38)

The composition or kit of any one of claims 36-38, wherein the Cas9 crRNA comprises a 20-nt guide sequence complimentary to a target DNA site with an A or Z content from 35% to 60%.

### Claim 40 (depends on 36, 37, 38, 39)

The composition or kit of any one of claims 36-39, wherein the Cas9 crRNA comprises a 20-nt guide sequence complimentary to a target DNA site with an AT or ZT content from 45% to 90%.

### Claim 41 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The composition or kit of any one of claims 36-49, wherein the Cas9 tracrRNA comprises at least one Z base.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The composition or kit of any one of claims 36-41, wherein the Cas9 tracrRNA does not comprise an A base.

### Claim 43

A method of cleaving or modifying a target DNA, comprising:
contacting the target DNA or a cell comprising the target DNA with:
(a) a Cas9 protein, or a nucleic acid encoding the Cas9 protein;
(b) a Cas9 crRNA comprising at least one Z base, and
(c) a Cas9 tracrRNA;
wherein the Cas9 protein, the Cas9 crRNA, and the Cas9 tracrRNA form a complex that cleaves or modifies the target DNA.

### Claim 44 (depends on 43)

The method of claim 43, wherein the Cas9 crRNA comprises at least 12 Z bases.

### Claim 45 (depends on 43, 44)

The method of claim 43 or 44, wherein the Cas9 crRNA does not comprise an A base.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claims 43-45, wherein the Cas9 crRNA comprises a 20-nt guide sequence complimentary to a target DNA site with an A or Z content from 35% to 60%.

### Claim 47 (depends on 43, 44, 45, 46)

The method of any one of claims 43-46, wherein the Cas9 crRNA comprises a 20-nt guide sequence complimentary to a target DNA site with an AT or ZT content from 45% to 90%.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the Cas9 tracrRNA comprises at least one Z base.

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The method of any one of claims 43-48, wherein the Cas9 tracrRNA does not comprise an A base.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 43-49, wherein the target DNA is a plasmid DNA.

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 43-50, wherein the target DNA comprises at least one Z base.

### Claim 52

A method of cleaving or modifying a target DNA comprising at least one Z base, comprising:
contacting the target DNA with:
(a) a Cas9 protein or a nucleic acid encoding the Cas9 protein; and
(b) a Cas9 guide RNA (gRNA) or a nucleic acid encoding a Cas9 gRNA,
wherein the Cas9 protein and the Cas9 gRNA form a complex that cleaves or modifies the target DNA comprising at least one Z base.

### Claim 53 (depends on 52)

The method of claim 52, wherein the target DNA comprises a Z base in a spacer region or a PAM region or both.

### Claim 54 (depends on 52, 53)

The method of claim 52 or 53, wherein the target DNA is a plasmid DNA.

### Claim 55

A method of modifying a target DNA comprising:
contacting the target DNA or a cell comprising the target DNA with:
(a) a Cas9-guided base editor or a nucleic acid encoding the Cas9-guided base editor; and
(b) a Cas9 crRNA comprising at least one Z base; and
(c) a Cas9 tracrRNA,
wherein the Cas9-guided base editor, the Cas9 crRNA, and the Cas9 tracrRNA form a complex that induces a base change of the target DNA.

### Claim 56 (depends on 55)

The method of claim 55, wherein the Cas9-guided base editor is an adenine base editor (ABE).

### Claim 57 (depends on 55, 56)

The method of claim 55 or 56, wherein the Cas9-guided base editor is ABE8e.

### Claim 58 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein the Cas9-guided base editor, the Cas9 crRNA, and the Cas9 tracrRNA form a complex that induces a A-to-G change of the target DNA.

### Claim 59 (depends on 58)

The method of claim 58, wherein the Cas9-guided base editor, the Cas9 crRNA, and the Cas9 tracrRNA form a complex that induces A-to-G changes with a frequency of at least 5%.

### Claim 60 (depends on 55, 56, 57, 58, 59)

The method of any one of claims 55-59, wherein the Cas9 crRNA comprises at least 8 Z bases.

### Claim 61 (depends on 55, 56, 57, 58, 59, 60)

The method of any one of claims 55-60, wherein the Cas9 crRNA does not comprise an A base.

### Claim 62 (depends on 61)

The method of claim 61, wherein the cell is a mammalian cell.
